How likely are my patients to be covered for DUPIXENT?

DUPIXENT has the #1 best access among specialty systemic therapies indicated for prurigo nodularis.^2,a,b

≈96% of commercial PN patients (18+ years of age) nationally are covered for DUPIXENT
≈83% of commercial patient lives have to fail only 1 or 2 prescription topical treatments

^aMMIT Analysis, March 2026. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, lebrikizumab, and nemolizumab.

^bBased on available published commercial UM coverage criteria.